Sign in
Enrolling by invitationPhase 2

Amyloid scans with 124I-evuzamitide in back and wrist nerve conditions

Tests amyloid scans in spinal stenosis or carpal tunnel syndrome.

Key facts

Who runs it
University of Tennessee Graduate School of Medicine
Where
Knoxville, United StatesSee the site
Trial code
Registry title
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
Status
Enrolling by invitation
Phase
Phase 2
People taking part
40 people, planned
Started
22 May 2025
Expected to end
May 2027
Type of study
Interventional
Treatments tested
  • 124I-evuzamitide
Record updated
21 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 60 or older who had spine or carpal tunnel surgery and whose removed tissue tested positive for amyloid (a protein build-up).

Age
60 years or older
Sex
All sexes
Disease stage
Tissue from laminectomy or carpal tunnel release surgery must be Congo red positive, with either extensive or mild/moderate amyloid. Mild/moderate amyloid also needs at least one other bone or joint problem, such as carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, biceps tendon rupture or joint replacement.
Earlier treatment
Laminectomy or carpal tunnel release surgery with a tissue sample tested. People taking heparin or heparin derivatives for anticoagulation cannot join.
Biomarker or test result
Congo red positive ligamentum flavum or tenosynovial tissue sample.

Main reasons for not taking part

  • On dialysis
  • Confirmed systemic amyloidosis outside muscle and bone tissue
  • Taking heparin or heparin derivatives for anticoagulation
  • Cannot lie still for about 40 minutes on the PET/CT scanner
  • History of iodine (potassium iodide) allergy

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Must be ≥ 60 years of age
  • Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements
  • Must have a Congo red positive ligamentum flavum or tenosynovial specimen analysis after laminectomy or carpal tunnel release surgery that is visually categorized as either "extensive" amyloid load or "mild/moderate" amyloid load by an experienced reviewer
  • Those with mild/moderate amyloid load in the connective tissue who also have a history of at least one other orthopedic clinical manifestation, including, but not limited to, carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, biceps tendon rupture, and shoulder/hip/knee arthroplasty
  • Females must be non-pregnant and non-lactating

Who cannot take part

  • History of iodine (potassium iodide) allergy
  • Subjects on dialysis
  • Subjects with a confirmed diagnosis of systemic amyloidosis, other than musculoskeletal tissue
  • Inability or unwillingness to comply with the study requirements
  • Subjects taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation
  • Inability to lie still for ~40 minutes on the PET/CT scanner
  • Other reason that would make the subject inappropriate for entry into this study

Where in United States

  • University of Tennessee Graduate School of MedicineKnoxville, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history of lumbar spinal stenosis and/or carpal tunnel syndrome.

The group in the trial

  • BiodistributionTreatment being tested

    Participants will be administered \~1 mCi of 124I-evuzamitide (up to 1 mg of peptide) by IV push at a proposed rate of \~1 mL per 5 seconds. Three hours after injection, a PET/CT image acquisition from shoulder to thigh as well as a 10 min static PET image of the heart will be performed.

    Treatment: 124I-evuzamitide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
PET/CT Imaging Of Subjects With Lumbar Spinal Stenosis Or Carpal Tunnel Syndrome Using Amyloid-Reactive Peptide 124I-Evuzamitide
Plain-language title
Amyloid scans with 124I-evuzamitide in back and wrist nerve conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
21 July 2026